581 related articles for article (PubMed ID: 16277179)
1. [Fluorescence cystoscopy in the diagnostics and treatment of superficial urinary bladder tumors].
Babjuk M; Soukup V; Petrík R; Pavlík I; Jirsa M; Dvorácek J; Pecen L
Cas Lek Cesk; 2005; 144 Suppl 2():15-8. PubMed ID: 16277179
[TBL] [Abstract][Full Text] [Related]
2. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
Babjuk M; Soukup V; Petrík R; Jirsa M; Dvorácek J
BJU Int; 2005 Oct; 96(6):798-802. PubMed ID: 16153204
[TBL] [Abstract][Full Text] [Related]
3. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors.
Filbeck T; Pichlmeier U; Knuechel R; Wieland WF; Roessler W
J Urol; 2002 Jul; 168(1):67-71. PubMed ID: 12050494
[TBL] [Abstract][Full Text] [Related]
4. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy.
Kriegmair M; Zaak D; Rothenberger KH; Rassweiler J; Jocham D; Eisenberger F; Tauber R; Stenzl A; Hofstetter A
J Urol; 2002 Aug; 168(2):475-8. PubMed ID: 12131291
[TBL] [Abstract][Full Text] [Related]
5. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study.
Schumacher MC; Holmäng S; Davidsson T; Friedrich B; Pedersen J; Wiklund NP
Eur Urol; 2010 Feb; 57(2):293-9. PubMed ID: 19913351
[TBL] [Abstract][Full Text] [Related]
6. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
Grossman HB; Gomella L; Fradet Y; Morales A; Presti J; Ritenour C; Nseyo U; Droller MJ;
J Urol; 2007 Jul; 178(1):62-7. PubMed ID: 17499283
[TBL] [Abstract][Full Text] [Related]
7. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
Denzinger S; Burger M; Walter B; Knuechel R; Roessler W; Wieland WF; Filbeck T
Urology; 2007 Apr; 69(4):675-9. PubMed ID: 17445650
[TBL] [Abstract][Full Text] [Related]
8. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.
Daniltchenko DI; Riedl CR; Sachs MD; Koenig F; Daha KL; Pflueger H; Loening SA; Schnorr D
J Urol; 2005 Dec; 174(6):2129-33, discussion 2133. PubMed ID: 16280742
[TBL] [Abstract][Full Text] [Related]
9. [The impact of ALA (5-aminolevulinic acid)-fluorescence detection on the prognosis of superficial bladder cancer].
Daniltchenko D; Riedl C; Koenig F; Daha LK; Sachs M; Schnorr D
Aktuelle Urol; 2004 Nov; 35(6):497-501. PubMed ID: 15526230
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
11. Management of low grade papillary bladder tumors.
Herr HW; Donat SM; Reuter VE
J Urol; 2007 Oct; 178(4 Pt 1):1201-5; discussion 1205. PubMed ID: 17698090
[TBL] [Abstract][Full Text] [Related]
12. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.
Hermann GG; Mogensen K; Carlsson S; Marcussen N; Duun S
BJU Int; 2011 Oct; 108(8 Pt 2):E297-303. PubMed ID: 21414125
[TBL] [Abstract][Full Text] [Related]
13. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence.
Kriegmair M; Baumgartner R; Knüchel R; Stepp H; Hofstädter F; Hofstetter A
J Urol; 1996 Jan; 155(1):105-9; discussion 109-10. PubMed ID: 7490803
[TBL] [Abstract][Full Text] [Related]
14. Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection.
Zaak D; Frimberger D; Stepp H; Wagner S; Baumgartner R; Schneede P; Siebels M; Knüchel R; Kriegmair M; Hofstetter A
J Urol; 2001 Nov; 166(5):1665-8; discussion 1668-9. PubMed ID: 11586198
[TBL] [Abstract][Full Text] [Related]
15. [Value of the photodynamic method in the diagnosis of superficial bladder tumors].
Lipiński MI; Jeromin LM
Wiad Lek; 2004; 57 Suppl 1():192-5. PubMed ID: 15884237
[TBL] [Abstract][Full Text] [Related]
16. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
[TBL] [Abstract][Full Text] [Related]
17. [ALA fluorescent diagnosis of bladder cancer].
Al'-Shukri SKh; Danil'chenko DI; Kënig F; Shnorr D
Urologiia; 2000; (5):48-50. PubMed ID: 11392226
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial.
Goebell PJ; Otto T; Suhr J; Rübben H
J Urol; 2002 Jul; 168(1):72-5. PubMed ID: 12050495
[TBL] [Abstract][Full Text] [Related]
19. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder.
Hungerhuber E; Stepp H; Kriegmair M; Stief C; Hofstetter A; Hartmann A; Knuechel R; Karl A; Tritschler S; Zaak D
Urology; 2007 Feb; 69(2):260-4. PubMed ID: 17320660
[TBL] [Abstract][Full Text] [Related]
20. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
Jocham D; Witjes F; Wagner S; Zeylemaker B; van Moorselaar J; Grimm MO; Muschter R; Popken G; König F; Knüchel R; Kurth KH
J Urol; 2005 Sep; 174(3):862-6; discussion 866. PubMed ID: 16093971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
